Orum Therapeutics Inc is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is principally engaged in the research and development of new biopharmaceuticals for cancer and immune diseases based on its platforms.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
07/08/26	₩61,900.00	+5.81%	132,083
06/08/26	₩58,500.00	-0.85%	101,810
05/08/26	₩59,000.00	+1.90%	159,215
04/08/26	₩57,900.00	+19.50%	310,331
03/08/26	₩48,450.00	+8.63%	123,818

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 07/08/2026			5-day change	1st Jan Change
61,900.00 ^KRW	+5.81%		+38.79%	-48.42%

07-15	Alert wrongly tagged to Orum Therapeutics withdrawn	RE
04-17	Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate	CI

Market Cap	1,344B 954M 825M 771M 707M 1.33B 90.78B 1.35B 9.04B 3.55B 45.5B 3.58B 3.5B 150B	P/E 2024 *	-	P/E 2025	-59.5x
Enterprise Value	1,237B 878M 759M 709M 651M 1.22B 83.55B 1.24B 8.32B 3.27B 41.88B 3.3B 3.22B 138B	EV / Sales 2024 *	-	EV / Sales 2025	103,580x
Free-Float	84.16%	Yield 2024 *	-	Yield 2025	-

07-15	Alert wrongly tagged to Orum Therapeutics withdrawn	RE
04-17	Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate	CI
04-13	Orum Therapeutics, Inc. Appoints Maria Koehler and Geoff Meyerson to Board of Directors	CI
01-16	Orum Therapeutics, Inc. announced that it has received KRW 24.999873175 billion in funding from a group of investors	CI
01-05	Orum Therapeutics Appoints Chad May as Chief Scientific Officer	CI
12-18	Orum Therapeutics, Inc. announced that it expects to receive KRW 24.999873175 billion in funding from a group of investors	CI
11-04	Orum Therapeutics Announces Presentation of Preclinical Data for Orm-1153 At the 2025 American Society of Hematology Annual Meeting	CI
15/10/25	Orum Therapeutics Appoints Dorin Toader as Head of Platform Technology	CI
23/06/25	Orum Therapeutics, Inc.(KOSDAQ:A475830) added to S&P Global BMI Index	CI
07/02/25	Orum Therapeutics, Inc. has completed an IPO in the amount of KRW 50 billion.	CI
16/07/24	Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex Pharmaceuticals for the Use of Orum's TPD2 Technology to Develop Novel Degrader-Antibody Conjugates	CI

12-19	Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases	AQ
15/10/25	Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orums Degrader-Antibody Conjugate Payload Platforms and Expand TPD Therapeutic Applications	AQ

Orum Therapeutics, Inc. Stock

Stocks

A475830

KR7475830006

Biotechnology & Medical Research

Valuation: Orum Therapeutics, Inc.

Chart: Orum Therapeutics, Inc.

Latest news : Orum Therapeutics, Inc.

Press Releases: Orum Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Orum Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+5.81%
1 week	+38.79%
Current month	+38.79%
1 month	+21.85%
3 months	-27.60%
6 months	-43.21%
Current year	-48.42%

1 week	42,400	62,200
1 month	36,100	62,200
Current year	36,100	146,600
1 year	22,050	146,600
3 years	15,950	146,600
5 years	15,950	146,600
10 years	15,950	146,600

Manager	Title	Age	Since
Seung-Ju Lee CEO	Chief Executive Officer	52	17/08/2016
In-Tae Jeong DFI	Director of Finance/CFO	44	23/10/2023
Chad May CTO	Chief Tech/Sci/R&D Officer	-	05/01/2026

Director	Title	Age	Since
Seung-Ju Lee BRD	Director/Board Member	52	17/08/2016
In-Tae Jeong BRD	Director/Board Member	44	23/10/2023
Un-Nam Park BRD	Director/Board Member	55	01/04/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/21/25 A	Seung-Ju Lee	Free	Founder	3,388,000	-
2/21/25 A	In-Tae Jeong	Free	Chief Financial Officer	10,000	-
2/21/25 A	Un-Nam Park	Free	Director	60,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORUM THERAPEUTICS, INC.	+5.81%	+38.79%	+167.97%	-	954M
WUXI APPTEC CO., LTD.	+8.49%	+20.55%	+69.74%	+109.30%	68.12B
ARGENX SE	+1.25%	+2.44%	+32.55%	+72.63%	55.18B
INSMED INCORPORATED	-1.09%	+32.96%	+19.95%	+499.45%	28.63B
BIONTECH SE	+2.72%	+3.41%	-15.88%	-4.90%	23.53B
WUXI BIOLOGICS (CAYMAN) INC.	+10.83%	+18.38%	+52.76%	+4.58%	23.99B
GENMAB A/S	+6.50%	+7.56%	+38.20%	-21.33%	18.45B
PHARMAESSENTIA CORPORATION	-3.88%	+16.98%	+199.30%	+354.30%	15.83B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.20%	+11.51%	+34.94%	+681.88%	16.44B
EXELIXIS, INC.	+3.58%	+1.96%	+44.61%	+167.01%	13.4B
Average	+4.04%	+13.29%	+64.41%	+206.99%	26.45B
Weighted average by Cap.	+4.36%	+13.15%	+49.91%	+168.49%

	2024	2025
Net sales	20.91B 14.83M 12.83M 11.98M 10.99M 20.67M 1.41B 21M 141M 55.17M 708M 55.7M 54.48M 2.34B	23.56M 16.72K 14.46K 13.51K 12.39K 23.3K 1.59M 23.67K 158K 62.19K 798K 62.78K 61.41K 2.64M
Net income	-5.74B -4.07M -3.52M -3.29M -3.02M -5.68M -388M -5.77M -38.6M -15.15M -194M -15.29M -14.96M -642M	-41.97B -29.78M -25.76M -24.05M -22.07M -41.5M -2.83B -42.16M -282M -111M -1.42B -112M -109M -4.7B
Net Debt	-90.47B -64.19M -55.52M -51.85M -47.56M -89.46M -6.11B -90.88M -608M -239M -3.06B -241M -236M -10.12B	-107B -75.99M -65.73M -61.38M -56.31M -106M -7.23B -108M -720M -283M -3.62B -285M -279M -11.98B